Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedRelated Topics section no longer displays links for Prostate Cancer and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check9 days agoChange DetectedAdded related topics: Prostate cancer and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check16 days agoChange DetectedA consolidated Locations section was added, listing Massachusetts and New Hampshire sites (replacing the previous separate Massachusetts Locations and New Hampshire Locations). The HHS Vulnerability Disclosure link was removed and the site revision tag updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.3.2 was added. Prostate cancer and related topic MedlinePlus Genetics were removed; Revision: v3.3.1 was removed.SummaryDifference0.2%

- Check45 days agoChange DetectedThe page's metadata was updated to include a 'Prostate cancer' tag and related topic 'MedlinePlus Genetics', and the revision label changed from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedThe government funding operating-status notice has been removed from the page. Core trial information such as description, eligibility, design, and outcome measures remains unchanged.SummaryDifference0.4%

Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.